AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?

Vaccine

Volumn 35, Issue 35, 2017, Pages 4470-4474

  Reperant, Leslie A ^a   Osterhaus, Albert D M E ^a,b  

^a Artemis One Health   (Netherlands)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Emerging; Epidemics; Preparedness; Virus

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AVIAN INFLUENZA; CHIKUNGUNYA; DENGUE; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY; MOSQUITO VECTOR; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VIRUS IDENTIFICATION; ZIKA FEVER; AFRICA; ANIMAL; ASIA; COMMUNICABLE DISEASE; CORONAVIRUS INFECTION; EUROPE; GLOBAL HEALTH; INFLUENZA; STATISTICS AND NUMERICAL DATA; TRANSMISSION; UNITED STATES;

ANTIVIRUS AGENT; VIRUS VACCINE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; ANIMALS; ANTIVIRAL AGENTS; ASIA; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; EUROPE; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS; INFLUENZA, HUMAN; PANDEMICS; SEVERE ACUTE RESPIRATORY SYNDROME; UNITED STATES; VIRAL VACCINES; ZIKA VIRUS INFECTION;

EID: 85020498017     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.04.082     Document Type: Review

References (45)

1. Reperant, L.A., Cornaglia, G., Osterhaus, A.D.M.E., The importance of understanding the human-animal interface. From early hominins to global citizens. Curr Top Microbiol Immunol 365 (2013), 49–81.
2. Waters, C.N., et al. The Anthropocene is functionally and stratigraphically distinct from the Holocene. Science, 351, 2016, aad2622.
3. Sanders, J.W., Fuhrer, G.S., Johnson, M.D., Riddle, M.S., The epidemiological transition: the current status of infectious diseases in the developed world versus the developing world. Sci Prog 91 (2008), 1–37.
4. de Swart, R.L., Duprex, W.P., Osterhaus, A.D., Rinderpest eradication: lessons for measles eradication?. Curr Opin Virol 2 (2012), 330–334.
5. Gao, F., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397 (1999), 436–441.
6. World_Health_Organization. (ed. World_Health_Organization), 2017.
7. Barre-Sinoussi, F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983), 868–871.
8. Dalgleish, A.G., et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984), 763–767.
9. Public_Health_Service, D.o.H.a.H.S., 1987.
10. Borducchi, E.N., et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540 (2016), 284–287.
11. Reperant, L.A., Kuiken, T., Osterhaus, A.D., Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans. Vaccine 30 (2012), 4419–4434.
12. Dawood, F.S., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12 (2012), 687–695.
13. Reperant, L.A., Rimmelzwaan, G. & Osterhaus, A.D.M.E. Recent advances in influenza vaccination. F1000Prime Rep 6, 47- (2014).
14. Hancock, K., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361 (2009), 1945–1952.
15. Clark, T.W., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361 (2009), 2424–2435.
16. Greenberg, M.E., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361 (2009), 2405–2413.
17. Chen, H., et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 15 (2009), 1849–1850.
18. Liang, X.F., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375 (2010), 56–66.
19. Reperant, L.A., Rimmelzwaan, G.F. & Osterhaus, A.D. Advances in influenza vaccination. F1000Prime Rep 6, 47, 2014.
20. Kiley, M.P., et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses?. Intervirology 18 (1982), 24–32.
21. Olival, K.J., Hayman, D.T., Filoviruses in bats: current knowledge and future directions. Viruses 6 (2014), 1759–1788.
22. Chan, M. in Women in Science Lecture Series (ed. World_Health_Organization) (London School of Hygiene and Tropical Medicine, 2015).
23. Chappell, K.J., Watterson, D., Fighting Ebola: a window for vaccine re-evaluation?. PLoS Pathog, 13, 2017, e1006037.
24. Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., Stohr, K., The severe acute respiratory syndrome. N Engl J Med 349 (2003), 2431–2441.
25. Drosten, C., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1967–1976.
26. Fouchier, R.A., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature, 423, 2003, 240.
27. Li, W., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003), 450–454.
28. Song, H.D., et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Nat Acad Sci USA 102 (2005), 2430–2435.
29. Li, W., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 (2005), 676–679.
30. Haagmans, B.L., et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10 (2004), 290–293.
31. Lin, J.T., et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther 12 (2007), 1107–1113.
32. Martin, J.E., et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26 (2008), 6338–6343.
33. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
34. Raj, V.S., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
35. Wang, Q., et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 16 (2014), 328–337.
36. World_Health_Organization, 2017.
37. Haagmans, B.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 (2016), 77–81.
38. World_Health_Organization, 2017.
39. Smalley, C., Erasmus, J.H., Chesson, C.B., Beasley, D.W., Status of research and development of vaccines for chikungunya. Vaccine 34 (2016), 2976–2981.
40. Hayes, E.B., Zika virus outside Africa. Emerg Infect Dis 15 (2009), 1347–1350.
41. Broutet, N., et al. Zika virus as a cause of neurologic disorders. N Engl J Med 374 (2016), 1506–1509.
42. Tripp, R.A., Ross, T.M., Development of a Zika vaccine. Expert Rev Vaccines 15 (2016), 1083–1085.
43. Cleaveland, S., Laurenson, M.K., Taylor, L.H., Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Philos Trans Roy Soc Lond B Biol Sci 356 (2001), 991–999.
44. Sims, L.D., Peiris, M., One health: the Hong Kong experience with avian influenza. Curr Top Microbiol Immunol 365 (2013), 281–298.
45. Khan, S.U., et al. A randomized controlled trial of interventions to impede date palm sap contamination by bats to prevent nipah virus transmission in Bangladesh. PLoS One, 7, 2012, e42689.